Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases

References

• Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig 2021;59:709–40.
   PubMed Web of Science ®Google Scholar
• Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, et al. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations. Front Immunol 2021;12:684699.
   PubMed Web of Science ®Google Scholar
• Sevilla JPH, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Res Ther 2023;25:118.
   PubMed Web of Science ®Google Scholar
• Vacchi C, Sebastiani M, Cassone G, Cerri S, Della CG, Salvarani C, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med 2020;9:407.
   PubMed Web of Science ®Google Scholar
• Gao Y, Moua T. Treatment of the connective tissue disease–related interstitial lung diseases: a narrative review. Mayo Clin Proc 2020;95:554–73.
   PubMed Web of Science ®Google Scholar
• Erre GL, Sebastiani M, Manfredi A, Gerratana E, Atzeni F, Passiu G, et al. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs Context 2021;10:2020-8–6.
   Google Scholar
• Molina-Molina M, Castellví I, Valenzuela C, Ramirez J, Rodríguez Portal JA, Franquet T, et al. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022;16:765–74.
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011;38:1636–43.
   PubMed Web of Science ®Google Scholar
• Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 2012;14:275–85.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: survival patterns in a population-based cohort. J Clin Med 2021;10:4830.
   PubMed Web of Science ®Google Scholar
• Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J 2023;61:2103187.
   PubMed Web of Science ®Google Scholar
• Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51:1800692.
   PubMed Web of Science ®Google Scholar
• Yang M, Wu Y, Liu X, Zhao C, Li T, Li T, et al. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: a systematic review and meta-analysis. Respir Med 2023;216:107329.
   PubMed Web of Science ®Google Scholar
• Boleto G, Avouac J, Allanore Y. The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease. Ther Adv Musculoskelet Dis 2022;14:1759720X211066686.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med 2019;380:2518–28.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON on behalf of the SENSCIS-ON trial investigators. Ann Rheum Dis 2022;81:1722–9.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–27.
   PubMed Web of Science ®Google Scholar
• Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a mericand, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8:453–60.
   PubMed Web of Science ®Google Scholar
• Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, et al. Nintedanib in patients with autoimmune disease–related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol 2022;74:1039–47.
   PubMed Web of Science ®Google Scholar
• Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Ann Rheum Dis 2020;79:1478–84.
   PubMed Web of Science ®Google Scholar
• Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M, et al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res 2022;23:85.
   PubMed Web of Science ®Google Scholar
• Ogura T, Inoue Y, Azuma A, Homma S, Kondoh Y, Tanaka K, et al. Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: interim report of a post-marketing surveillance in Japan. Adv Ther 2023;40:1474–93.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Sekine A, Baba T, Katano T, Tabata E, Shintani R, et al. Low starting-dosage of nintedanib for the reduction of early termination. Respir Investig 2019;57:282–5.
   PubMed Web of Science ®Google Scholar
• Di Battista M, Tavanti L, Pistelli F, Carrozzi L, Da Rio M, Rossi A, et al. Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects. Inflammopharmacology 2023;31:2445–9.
   PubMed Web of Science ®Google Scholar
• Nili M, Epstein AJ, Nunag D, Olson A, Borah B. Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients. BMC Pulm Med 2023;23:230.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, Soon Kim D, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079–87.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 2013;65:2737–47.
   PubMed Web of Science ®Google Scholar
• Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, De Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017;3:e000507.
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017;69:35–45.
   PubMed Web of Science ®Google Scholar
• Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American College of rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022;81:321–6.
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400–12.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan Research Committee of the Ministry of Health, Labor, and Welfare for systemic autoimmune diseases. Mod Rheumatol 2021;31:29–33.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
   PubMed Web of Science ®Google Scholar
• Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, Du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976–87.
   PubMed Web of Science ®Google Scholar
• Kubota M, Kobayashi H, Quanjer PH, Omori H, Tatsumi K, Kanazawa M. Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values. Respir Investig 2014;52:242–50.
   PubMedGoogle Scholar
• Tsuneyoshi S, Zaizen Y, Tominaga M, Matama G, Umemoto S, Ohno S, et al. Clinical significance of high monocyte counts for the continuous treatment with nintedanib. BMC Pulm Med 2023;23:242.
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Abe M, Terada J, Sakayori M, Suzuki K, Yoshioka K, et al. Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2020;62:101917.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Kuwana M. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 2020;16:547–60.
   PubMed Web of Science ®Google Scholar
• Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration 2019;97:173–84.
   PubMed Web of Science ®Google Scholar